Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	AOCI Attributable to Parent [Member]	Parent [Member]	Noncontrolling Interest [Member]	Total
Balance at Mar. 31, 2023	$ 830	$ 42,254,154	$ (42,197,663)	$ (30,328)	$ 665	$ 27,658		$ 27,658
Balance, shares at Mar. 31, 2023	829,626
Shares issued for stock investment	$ 250	1,749,750				1,750,000		1,750,000
Shares issued for stock investment, shares	250,000
Exercise of warrants	$ 30	305,970				306,000		306,000
Exercise of warrants, shares	30,600
Deemed dividend for warrant extension		1,387,662	(1,387,662)
Cash distribution		(775)				(775)		(775)
Foreign currency translation adjustment					(3,513)	(3,513)		(3,513)
Net loss			(298,202)			(298,202)		(298,202)
Balance at Mar. 31, 2024	$ 1,110	45,696,761	(43,883,527)	(30,328)	(2,848)	1,781,168		1,781,168
Balance, shares at Mar. 31, 2024	1,110,226
Exercise of warrants	$ 93	895,100				895,193		895,193
Exercise of warrants, shares	92,776
Foreign currency translation adjustment					618,233	618,233		618,233
Net loss			(2,901,321)			(2,901,321)	(15,959)	(2,917,280)
Common Stock issued in Orocidin business combination	$ 3,800	18,996,200				19,000,000		19,000,000
Common Stock issued in Orocidin business combination, shares	3,800,000
Cancellation of liability-classified warrants – Related party		167,000				167,000		167,000
Common Stock issued for services	$ 30	138,949				138,979		$ 138,979
Common Stock issued for services, shares	30,000							30,000
Forgiveness of debt - related party		13,886				13,886		$ 13,886
Vesting of restricted stock units - ESG Advisory Group	$ 20	(20)
Vesting of restricted stock units - ESG Advisory Group, shares	19,500
Recognition of non-controlling interest in acquisition of Orocidin							450,000	450,000
Orocidin issuance of common stock in capital raise		183,663				183,663	9,667	193,330
Stock-based compensation		527,625				527,625		527,625
Common Stock issued in Bio-Convert business combination, net (See Note 10)	$ 12,000	38,985,120				38,997,120		38,997,120
Common Stock issued in Bio-Convert business combination, net, shares	12,000,000
Common Stock issued to acquire remaining equity of Orocidin (See Note 10)	$ 200	443,508				443,708	(443,708)
Common Stock issued to acquire remaining equity of Orocidin, shares	200,000
Balance at Mar. 31, 2025	$ 17,253	$ 106,047,792	$ (46,784,848)	$ (30,328)	$ 615,385	$ 59,865,254		$ 59,865,254
Balance, shares at Mar. 31, 2025	17,252,502

Nordicus Partners Corp 10-K